Akeso Biopharma, a Chinese biotech company specialized in innovative antibody drugs, announced on Monday the completion of a $150 million Series D round of financing led by China-focused private equity firm Loyal Valley Capital (LVC) and Hong Kong-listed Sino Biopharm.
Chinese government-backed venture capital firm Shenzhen Capital Group (SZVC), Lake Blue Healthcare Fund, Hong Kong-based conglomerate K. Wah Group, Chinese asset management company CCB Capital, and Shenzhen-based Triwise Capital Management also joined the new round.
